Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Active Comparator 2 Clear all
Completed Phase 1Phase 2 Interventional

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

NCT06162728
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Briquilimab, Placebo
Drug · Other
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 4, 2026, 2:52 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects

NCT06964230
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
T3D-959, Placebo Comparator
Drug · Other
Lead sponsor
T3D Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Sep 4, 2026, 2:52 AM EDT
Completed Phase 4 Interventional

Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder

NCT00034580
View directory record Official record
Conditions
Bipolar Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
21
States / cities
Berkley, California • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2006 · Synced Sep 4, 2026, 2:52 AM EDT
Completed Not applicable Interventional Results available

Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries

NCT01412541
View directory record Official record
Conditions
Femoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion, Popliteal Artery Occlusion
Interventions
Standard Uncoated Angioplasty Balloon, Moxy Drug Coated Balloon
Procedure · Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
42
States / cities
Los Angeles, California • Oceanside, California • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 4, 2026, 2:52 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.

NCT06579105
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo (placebo matching AZD5004 film-coated tablet), AZD5004, Semaglutide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
50
States / cities
Mobile, Alabama • Sheffield, Alabama • Vestavia Hills, Alabama + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 4, 2026, 2:52 AM EDT
Not listed Phase 2 Interventional

IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

NCT04933799
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
PF-06650833, Matching Placebo
Drug
Lead sponsor
Giovanni Franchin, M.D, Ph.D
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 4, 2026, 2:52 AM EDT
Completed Phase 2 Interventional

A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes

NCT00486200
View directory record Official record
Conditions
Herpes Genitalis
Interventions
ASP2151, valacyclovir, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 4, 2026, 2:52 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03536884
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab, Secukinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Santa Ana, California • Danbury, Connecticut • Ocala, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 4, 2026, 2:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Biomarkers in Children to Help Parents Quit Tobacco

NCT04832659
View directory record Official record
Conditions
Tobacco Dependence
Interventions
CEASE, CEASE + BIO
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 4, 2026, 2:52 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT

NCT06149403
View directory record Official record
Conditions
MPS-IH (Hurler Syndrome)
Interventions
Experimental: OTL-203, Active Comparator: Allo-HSCT
Genetic
Lead sponsor
Orchard Therapeutics
Industry
Eligibility
28 Days to 30 Months
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 4, 2026, 2:52 AM EDT
Completed Phase 3 Interventional Results available

Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis

NCT02638259
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GP2015
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Peoria, Arizona • Phoenix, Arizona • El Cajon, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 4, 2026, 2:52 AM EDT
Terminated Phase 1Phase 2 Interventional

Tamoxifen Therapy for Myotubular Myopathy

NCT04915846
View directory record Official record
Conditions
X Linked Myotubular Myopathy
Interventions
ApoTamox 10mg, Placebo
Drug
Lead sponsor
James Dowling
Other
Eligibility
6 Months and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 4, 2026, 2:52 AM EDT
Recruiting Not applicable Interventional

Insomnia Behavioral Intervention Study

NCT05301543
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Experimental: Behavioral approach 1, Comparator: Behavioral approach 2
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 4, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

BIBW 2992 (Afatinib) in Head & Neck Cancer

NCT00514943
View directory record Official record
Conditions
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions
BIBW 2992, Cetuximab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
18
States / cities
Stanford, California • Chicago, Illinois • Harvey, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Sep 4, 2026, 2:52 AM EDT
Completed Phase 2 Interventional Results available

BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab

NCT02054481
View directory record Official record
Conditions
Psoriasis
Interventions
BI 655066, Ustekinumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Los Angeles, California • Port Orange, Florida • Arlington Hts, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2016 · Synced Sep 4, 2026, 2:52 AM EDT
Not yet recruiting Phase 4 Interventional

Comparative Effectiveness of Available Treatments for Sinus and Ear Infections in Children (Acute Otitis Media)

NCT07730814
View directory record Official record
Conditions
Acute Otitis Media (AOM)
Interventions
Amoxicillin, Amoxicillin-Clavulanate, Amoxicillin Placebo, Amoxicillin-Clavulanate Placebo
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
6 Months to 36 Months
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
5
States / cities
Denver, Colorado • Durham, North Carolina • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 4, 2026, 2:52 AM EDT
Not listed Phase 1 Interventional

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

NCT02059564
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
HM11260C, Placebo, Victoza
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
California City, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 4, 2026, 2:52 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers

NCT07064564
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naltrexone implant, 14.4 grams, Naltrexone implant, 9.6 grams, Extended-release naltrexone injection, 380 mg
Drug
Lead sponsor
Akyso Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 4, 2026, 2:52 AM EDT
Completed Phase 4 Interventional Results available

Treating Hearing Loss to Improve Mood and Cognition in Older Adults

NCT03321006
View directory record Official record
Conditions
Hearing Loss, Depression
Interventions
Phonak Audeo B-R 90 hearing aid device (Active), Duloxetine or escitalopram, Audeo B-R 90 hearing aid device (Sham)
Device · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Sep 4, 2026, 2:52 AM EDT
Completed Not applicable Interventional Results available

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

NCT01951339
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Disease
Interventions
Sitagliptin, Glimepiride, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
22 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Sep 4, 2026, 2:52 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Precision Dosing of Metformin in Youth With T2D

NCT06120881
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
10 Years to 21 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 4, 2026, 2:52 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Postpartum Urinary Retention With Essential Oils (PURE)

NCT03319498
View directory record Official record
Conditions
Urinary Retention
Interventions
Peppermint Oil Vapor, Mineral Oil Vapor
Other
Lead sponsor
Mount Carmel Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 4, 2026, 2:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

NCT01677299
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)
Drug
Lead sponsor
Elcelyx Therapeutics, Inc.
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Sep 4, 2026, 2:52 AM EDT
Suspended Phase 3 Interventional

Investigational Study of Delayed Release Metformin

NCT04854512
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Metformin DR, Metformin IR, Metformin DR Placebo, Metformin IR placebo
Drug
Lead sponsor
Anji Pharma
Industry
Eligibility
18 Years to 100 Years
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
33
States / cities
Glendale, Arizona • Mesa, Arizona • Apple Valley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Sep 4, 2026, 2:52 AM EDT